RetroSense Therapeutics Acquired by Allergan

On September 6, 2016, Allergan, a leading global pharmaceutical company, and RetroSense Therapeutics, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness, announced that Allergan has acquired substantially all of the assets of RetroSense in an all-cash transaction. Wilson Sonsini Goodrich & Rosati represented RetroSense in the transaction.

Under the terms of the agreement, Allergan has paid RetroSense a $60 million upfront payment and has agreed to potential regulatory and commercialization milestone payments related to its lead development program, RST-001, a novel gene therapy for the potential treatment of retinitis pigmentosa.

The WSGR team that represented RetroSense in the transaction included:

Corporate:
Dan Koeppen
Jason Skolnik
David Mashburn
Kassandra Castillo

Technology Transactions:
Miranda Biven
Alex Key
Pete Gutsche

Regulatory:
David Hoffmeister

Antitrust:
Paul Jin
Roisin Comerford

Employee Benefits and Compensation:
Brandon Gantus

Tax:
Greg Broome
Devin Heckman

Employment Litigation:
Briza Sanchez

For more information, click here to read the companies' joint press release.